Arcellx (NASDAQ:ACLX – Free Report) had its target price trimmed by Stifel Nicolaus from $54.00 to $52.00 in a research note released on Tuesday morning, MarketBeat reports. The firm currently has a buy rating on the stock. ACLX has been the subject of several other research reports. Barclays increased their price target on shares of […]
Cellular agriculture investor Agronomics announced on Thursday that its Shanghai-based investee CellX had opened a pioneering cultivated meat pilot factory in China.
Arcellx, Inc. (ACLX), a clinical-stage biotechnology company, announced that the U.S. Food and Drug Administration has lifted the partial clinical hold placed on its CART-ddBCMA investigational new drug for the treatment of patients with relapsed or refractory multiple myeloma or rrMM.
Shanghai-based CellX has launched China’s first cultivated meat pilot factory, a significant breakthrough in the nation’s quest for a sustainable source of animal protein to feed its population.
Arcellx (NASDAQ:ACLX – Get Free Report) and X4 Pharmaceuticals (NASDAQ:XFOR – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends and profitability. Insider and Institutional Ownership 63.2% of X4 Pharmaceuticals […]